Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents.

Khandazhinskaya AL, Matyugina ES, Solyev PN, Wilkinson M, Buckheit KW, Buckheit RW Jr, Chernousova LN, Smirnova TG, Andreevskaya SN, Alzahrani KJ, Natto MJ, Kochetkov SN, de Koning HP, Seley-Radtke KL.

Molecules. 2019 Sep 21;24(19). pii: E3433. doi: 10.3390/molecules24193433.

2.

The structure-activity profile of mercaptobenzamides' anti-HIV activity suggests that thermodynamics of metabolism is more important than binding affinity to the target.

Nikolayevskiy H, Robello M, Scerba MT, Pasternak EH, Saha M, Hartman TL, Buchholz CA, Buckheit RW Jr, Durell SR, Appella DH.

Eur J Med Chem. 2019 Sep 15;178:818-837. doi: 10.1016/j.ejmech.2019.06.020. Epub 2019 Jun 9.

PMID:
31252286
3.

Novel 5'-Norcarbocyclic Pyrimidine Derivatives as Antibacterial Agents.

Khandazhinskaya AL, Alexandrova LA, Matyugina ES, Solyev PN, Efremenkova OV, Buckheit KW, Wilkinson M, Buckheit RW Jr, Chernousova LN, Smirnova TG, Andreevskaya SN, Leonova OG, Popenko VI, Kochetkov SN, Seley-Radtke KL.

Molecules. 2018 Nov 23;23(12). pii: E3069. doi: 10.3390/molecules23123069.

4.

Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1.

Ali A, Ng HL, Blankson JN, Burton DR, Buckheit RW 3rd, Moldt B, Fulcher JA, Ibarrondo FJ, Anton PA, Yang OO.

J Infect Dis. 2018 Sep 22;218(9):1447-1452. doi: 10.1093/infdis/jiy346.

5.

Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.

Pereira LE, Singletary T, Martin A, Dinh CT, Deyounks F, Holder A, McNicholl J, Buckheit KW, Buckheit RW Jr, Ham A, Katz DF, Smith JM.

Drug Deliv Transl Res. 2018 Oct;8(5):1180-1190. doi: 10.1007/s13346-018-0538-0.

6.

Designing and developing suppository formulations for anti-HIV drug delivery.

Ham AS, Buckheit RW Jr.

Ther Deliv. 2017 Aug;8(9):805-817. doi: 10.4155/tde-2017-0056. Review.

7.

Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.

Luo M, Groaz E, Andrei G, Snoeck R, Kalkeri R, Ptak RG, Hartman T, Buckheit RW Jr, Schols D, De Jonghe S, Herdewijn P.

J Med Chem. 2017 Jul 27;60(14):6220-6238. doi: 10.1021/acs.jmedchem.7b00416. Epub 2017 Jul 6.

PMID:
28682067
8.

Lubricant Provides Poor Rectal Mucosal HIV Coverage.

Shieh EC, Weld ED, Fuchs EJ, Hiruy H, Buckheit KW, Buckheit RW Jr, Breakey J, Hendrix CW.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):784-787. doi: 10.1089/AID.2016.0318. Epub 2017 Jul 24.

9.

Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.

Guthrie KM, Rohan L, Rosen RK, Vargas SE, Shaw JG, Katz D, Kojic EM, Ham AS, Friend D, Buckheit KW, Buckheit RW Jr.

Pharm Dev Technol. 2018 Mar;23(3):311-314. doi: 10.1080/10837450.2017.1339085. Epub 2017 Jun 21.

10.

Probing Mercaptobenzamides as HIV Inactivators via Nucleocapsid Protein 7.

Saha M, Scerba MT, Shank NI, Hartman TL, Buchholz CA, Buckheit RW Jr, Durell SR, Appella DH.

ChemMedChem. 2017 May 22;12(10):714-721. doi: 10.1002/cmdc.201700141. Epub 2017 Apr 25.

11.

Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification.

Beadle JR, Valiaeva N, Yang G, Yu JH, Broker TR, Aldern KA, Harden EA, Keith KA, Prichard MN, Hartman T, Buckheit RW Jr, Chow LT, Hostetler KY.

J Med Chem. 2016 Dec 8;59(23):10470-10478. Epub 2016 Nov 28.

PMID:
27933957
12.

An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.

Bennett RP, Stewart RA, Hogan PA, Ptak RG, Mankowski MK, Hartman TL, Buckheit RW Jr, Snyder BA, Salter JD, Morales GA, Smith HC.

Antiviral Res. 2016 Dec;136:51-59. doi: 10.1016/j.antiviral.2016.11.001. Epub 2016 Nov 5.

13.

Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus.

Hartman TL, Yang L, Helfrick AN, Hassink M, Shank NI, George Rosenker K, Scerba MT, Saha M, Hughes E, Wang AQ, Xu X, Gupta P, Buckheit RW Jr, Appella DH.

Antiviral Res. 2016 Oct;134:216-225. doi: 10.1016/j.antiviral.2016.08.022. Epub 2016 Aug 26.

PMID:
27568924
14.

Short Communication: HIV Controller T Cells Effectively Inhibit Viral Replication in Alveolar Macrophages.

Walker-Sperling VE, Merlo CA, Buckheit RW 3rd, Lambert A, Tarwater P, Kirk GD, Drummond MB, Blankson JN.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1097-1099. Epub 2016 Aug 2.

15.

Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.

Hoshi A, Sakamoto T, Takayama J, Xuan M, Okazaki M, Hartman TL, Buckheit RW Jr, Pannecouque C, Cushman M.

Bioorg Med Chem. 2016 Jul 1;24(13):3006-3022. doi: 10.1016/j.bmc.2016.05.010. Epub 2016 May 24.

PMID:
27234889
16.

Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.

Srinivasan P, Zhang J, Martin A, Kelley K, McNicholl JM, Buckheit RW Jr, Smith JM, Ham AS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4140-50. doi: 10.1128/AAC.00082-16. Print 2016 Jul.

17.

The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development.

Morrow Guthrie K, Vargas S, Shaw JG, Rosen RK, van den Berg JJ, Kiser PF, Buckheit K, Bregman D, Thompson L, Jensen K, Johnson T, Buckheit RW.

PLoS One. 2015 Dec 22;10(12):e0145642. doi: 10.1371/journal.pone.0145642. eCollection 2015.

18.

Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques.

Pereira LE, Mesquita PM, Ham A, Singletary T, Deyounks F, Martin A, McNicholl J, Buckheit KW, Buckheit RW Jr, Smith JM.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1393-400. doi: 10.1128/AAC.02201-15.

19.

A Human Immunodeficiency Virus Controller With a Large Population of CD4(+)CD8(+) Double-Positive T Cells.

Durand CM, Buckheit RW 3rd, Salgado M, Pohlmeyer CW, Walker-Sperling VE, Hegarty RW, Ambinder RF, Blankson JN.

Open Forum Infect Dis. 2015 Mar 20;2(2):ofv039. doi: 10.1093/ofid/ofv039. eCollection 2015 Apr.

20.

Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.

Buckheit KW, Furlan-Freguia C, Ham AS, Buckheit RW.

Curr Top Med Chem. 2016;16(10):1118-34. Review.

PMID:
26324047
21.

Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.

Rosen RK, van den Berg JJ, Vargas SE, Senocak N, Shaw JG, Buckheit RW Jr, Smith KA, Guthrie KM.

Contraception. 2015 Dec;92(6):596-601. doi: 10.1016/j.contraception.2015.08.007. Epub 2015 Aug 11.

22.

An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission.

Ugaonkar SR, Clark JT, English LB, Johnson TJ, Buckheit KW, Bahde RJ, Appella DH, Buckheit RW Jr, Kiser PF.

J Pharm Sci. 2015 Oct;104(10):3426-39. doi: 10.1002/jps.24551. Epub 2015 Jul 6.

23.

The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.

Ham AS, Nugent ST, Peters JJ, Katz DF, Shelter CM, Dezzutti CS, Boczar AD, Buckheit KW, Buckheit RW Jr.

Antiviral Res. 2015 Aug;120:153-64. doi: 10.1016/j.antiviral.2015.06.010. Epub 2015 Jun 17.

24.

Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors.

Ham AS, Buckheit RW Jr.

Ther Deliv. 2015 Feb;6(2):217-29. doi: 10.4155/tde.14.110. Review.

25.

Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus.

Moulaei T, Alexandre KB, Shenoy SR, Meyerson JR, Krumpe LR, Constantine B, Wilson J, Buckheit RW Jr, McMahon JB, Subramaniam S, Wlodawer A, O'Keefe BR.

Retrovirology. 2015 Jan 23;12:6. doi: 10.1186/s12977-014-0127-3.

26.

Anti-HSV activity of serpin antithrombin III.

Quenelle DC, Hartman TL, Buckheit RW, Prichard MN, Lynn RG.

Int Trends Immun. 2014 Apr;2(2):87-92.

27.

Comparative analysis of the capacity of elite suppressor CD4+ and CD8+ T cells to inhibit HIV-1 replication in monocyte-derived macrophages.

Walker-Sperling VE, Buckheit RW 3rd, Blankson JN.

J Virol. 2014 Sep 1;88(17):9789-98. doi: 10.1128/JVI.00860-14. Epub 2014 Jun 18.

28.

Long-term control of viral replication in a Group O, human immunodeficiency virus type 1-infected individual.

Buckheit RW 3rd, Sexauer SB, Sedaghat AR, Wilke CO, Laeyendecker O, Basseth CR, Blankson JN.

AIDS Res Hum Retroviruses. 2014 Jun;30(6):511-3. doi: 10.1089/AID.2014.0054. No abstract available.

29.

Synthesis and Biological Evaluation of 5'-O-Dicarboxylic Fatty Acyl Monoester Derivatives of Anti-HIV Nucleoside Reverse Transcriptase Inhibitors.

Pemmaraju B, Agarwal HK, Oh D, Buckheit KW, Buckheit RW Jr, Tiwari R, Parang K.

Tetrahedron Lett. 2014 Mar 19;55(12):1983-1986.

30.

HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon.

Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, Blankson JN, Pardoll D, Cox AL.

PLoS Pathog. 2014 May 1;10(5):e1004082. doi: 10.1371/journal.ppat.1004082. eCollection 2014 May.

31.

HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Salgado M, Swanson MD, Pohlmeyer CW, Buckheit RW 3rd, Wu J, Archin NM, Williams TM, Margolis DM, Siliciano RF, Garcia JV, Blankson JN.

J Virol. 2014 Mar;88(6):3340-52. doi: 10.1128/JVI.03380-13. Epub 2014 Jan 3.

32.

CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants.

Pohlmeyer CW, Buckheit RW 3rd, Siliciano RF, Blankson JN.

Retrovirology. 2013 Dec 12;10:152. doi: 10.1186/1742-4690-10-152.

33.

"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels.

van den Berg JJ, Rosen RK, Bregman DE, Thompson LA, Jensen KM, Kiser PF, Katz DF, Buckheit K, Buckheit RW Jr, Morrow KM.

AIDS Behav. 2014 May;18(5):862-70. doi: 10.1007/s10461-013-0652-4.

34.

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties.

Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold BC.

Retrovirology. 2013 Oct 24;10:113. doi: 10.1186/1742-4690-10-113.

35.

Evolution of an attenuated HIV-1 isolate in an elite suppressor.

Salgado M, Gandhi S, Buckheit RW, Berkenblit GV, Blankson JN.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):284-8. doi: 10.1089/AID.2013.0229. Epub 2013 Nov 13.

36.

In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410.

Ham AS, Lustig W, Yang L, Boczar A, Buckheit KW, Buckheit RW Jr.

PLoS One. 2013 Sep 18;8(9):e75306. doi: 10.1371/journal.pone.0075306. eCollection 2013.

37.

Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410.

Buckheit RW Jr, Watson Buckheit K, Sturdevant CB, Buckheit RW 3rd.

Antiviral Res. 2013 Nov;100(2):382-91. doi: 10.1016/j.antiviral.2013.09.005. Epub 2013 Sep 19.

PMID:
24055450
38.

Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells.

Buckheit RW 3rd, Siliciano RF, Blankson JN.

Retrovirology. 2013 Jul 1;10:68. doi: 10.1186/1742-4690-10-68.

39.

Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors.

Buckheit RW 3rd, Salgado M, Silciano RF, Blankson JN.

J Virol. 2012 Dec;86(24):13679-88. doi: 10.1128/JVI.02439-12. Epub 2012 Oct 10.

40.

Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.

Dezzutti CS, Shetler C, Mahalingam A, Ugaonkar SR, Gwozdz G, Buckheit KW, Buckheit RW Jr.

Antiviral Res. 2012 Nov;96(2):221-5. doi: 10.1016/j.antiviral.2012.08.004. Epub 2012 Aug 23.

41.

The implications of viral reservoirs on the elite control of HIV-1 infection.

Buckheit RW 3rd, Salgado M, Martins KO, Blankson JN.

Cell Mol Life Sci. 2013 Mar;70(6):1009-19. doi: 10.1007/s00018-012-1101-7. Epub 2012 Aug 4. Review.

PMID:
22864624
42.

Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.

Agarwal HK, Buckheit KW, Buckheit RW Jr, Parang K.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5451-4. doi: 10.1016/j.bmcl.2012.07.037. Epub 2012 Jul 17.

43.

Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1.

Buckheit KW, Buckheit RW Jr.

Mol Biol Int. 2012;2012:781305. doi: 10.1155/2012/781305. Epub 2012 Jul 12.

44.

The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets.

Hartman TL, Buckheit RW Jr.

Mol Biol Int. 2012;2012:401965. doi: 10.1155/2012/401965. Epub 2012 Jul 10.

45.

Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs.

Buckheit RW 3rd, Allen TG, Alme A, Salgado M, O'Connell KA, Huculak S, Falade-Nwulia O, Williams TM, Gallant JE, Siliciano RF, Blankson JN.

Nat Commun. 2012 Mar 6;3:716. doi: 10.1038/ncomms1697.

46.

Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection.

Ham AS, Rohan LC, Boczar A, Yang L, W Buckheit K, Buckheit RW Jr.

Pharm Res. 2012 Jul;29(7):1897-907. doi: 10.1007/s11095-012-0715-7. Epub 2012 Mar 6.

47.

An algorithm for the preclinical development of anti-HIV topical microbicides.

Buckheit RW Jr, Buckheit KW.

Curr HIV Res. 2012 Jan 1;10(1):97-104.

PMID:
22264051
48.

Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.

Ham AS, Ugaonkar SR, Shi L, Buckheit KW, Lakougna H, Nagaraja U, Gwozdz G, Goldman L, Kiser PF, Buckheit RW Jr.

J Pharm Sci. 2012 Apr;101(4):1423-35. doi: 10.1002/jps.23026. Epub 2012 Jan 6.

PMID:
22227864
49.

Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

Salgado M, Rabi SA, O'Connell KA, Buckheit RW 3rd, Bailey JR, Chaudhry AA, Breaud AR, Marzinke MA, Clarke W, Margolick JB, Siliciano RF, Blankson JN.

Retrovirology. 2011 Dec 5;8:97. doi: 10.1186/1742-4690-8-97.

50.

Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents.

Hartman TL, Yang L, Buckheit RW Jr.

Antiviral Res. 2011 Dec;92(3):505-8. doi: 10.1016/j.antiviral.2011.10.013. Epub 2011 Oct 19.

Supplemental Content

Loading ...
Support Center